Leading NeuroSense Therapeutics (Nasdaq: $NRSN), a Clinical stage Biotech company, accelerating therapies for ALS and Neurodegenerative diseases.
Joined January 2020
- Tweets332
- Following2.5K
- Followers1.5K
- Likes353
Well said - I heard what you said firsthand, and to me it was clear that you do not endorse any candidate. But the press is the press - looking for stories and headlines. More importantly, thank you for your immense support for Israeli innovation and, particularly, for Israeli biotech innovation and the development of treatments for brain / CNS disorders. Thank you, Bill! @BillAckman
I want to make sure that a comment I made to the Israeli press is not misinterpreted. I spoke from my perspective as an American, and I don’t intend to weigh in on the upcoming Israeli election.
Furthermore, I don’t know all of the candidates; I am not an expert in Israeli politics; and therefore I don’t know who is the best choice for the country. This is obviously a decision best made by the Israeli citizens.
With respect to Neri, we agree on some politics and disagree on others. As an Israeli, she will vote in the election in a manner that she believes is best for Israel.
One shouldn’t draw any conclusions about my remarks on Israel as somehow implying anything about Neri’s politics and whom she intends to vote for.
Many have reached out recently, so I want to share a brief update with all stakeholders: our RoAD proof-of-concept study of PrimeC in Alzheimer's disease has completed, and the data are currently being analyzed by Prof. Steven Arnold and his team. We look forward to sharing the study outcomes through our formal communication channels in the coming days.
$NRSN
#AD
One of the most exciting developments in neurodegenerative disease research is our growing ability to measure disease biology directly through validated biomarkers.
A recent Nature Medicine publication highlighted the potential of plasma p-tau217 as a powerful blood-based biomarker for Alzheimer's disease, adding to the growing evidence supporting biomarkers as tools to better understand, diagnose, and potentially monitor disease progression. (Link in the first comment.)
At NeuroSense, samples from our Phase 2 Alzheimer's study are currently undergoing analysis, and we look forward to sharing the results later this month, consistent with our previously communicated Q2 2026 timeline.
#AlzheimersDisease
$NRSN
$NRSN
Glad to share that NeuroSense Therapeutics has been granted a new U.S. patent covering the use of our novel platform in Alzheimer’s disease, extending protection through 2043.
A meaningful IP milestone supporting long-term development and commercialization. 👉
$NRSN
Off on a 2-week business trip to NYC, Boston & CA 🇺🇸✈️
Busy schedule, but might squeeze in a meeting or two - feel free to ping me if you’re around.
I’ll be sharing updates along the way on Instagram:
👉 instagram.com/alonbennoon
NeuroSense reports that its Phase 2 proof-of-concept study of PrimeC in Alzheimer’s disease confirmed its primary endpoint of safety and tolerability;
Additional clinical and biomarker analyses expected in Q1 2026.
$NRSN #Alzheimers #Biotech
prnewswire.com/news-releases…
Major updates ahead. On December 8, I’ll host an investor meeting to share a comprehensive update on NeuroSense Therapeutics (Nasdaq: NRSN) and the catalysts shaping our next phase of growth.
We’ll cover:
🔹 ALS Phase 3 Trial (PARAGON ) - design, milestones, and expected catalysts
🔹 Binding term sheet - open, factual status and next steps
🔹 Canada pathway - Health Canada progress and potential acceleration
🔹 Alzheimer’s Phase 2 Trial (RoAD) - data insights and strategic direction
Recent months focused on groundwork. In the coming period we plan to prioritize execution and increased visibility.
We believe our scientific foundation positions us well as we advance.
*Registration link in the first comment below. ✍
#NeuroSense #NRSN #PrimeC #ALS #Alzheimers
#ClinicalTrials #Catalysts #Investors
$NRSN
Heading to Southern California for a conference and several key meetings. I’ve left time open to connect with founders, researchers, clinicians, and investors working in ALS and neuroscience.
DM me if you’d like to meet.
#ALS
#California
$NRSN
From PARADIGM to PARAGON:
On October 10 at NEALS 2025, Prof. Merit Cudkowicz will unveil the design of our global Phase 3 PARAGON trial of PrimeC in ALS.
Built on insights from our Phase 2b PARADIGM study, PARAGON is designed to rigorously confirm PrimeC’s potential to preserve function and change disease trajectory.
PrimeC - NeuroSense’s lead candidate, is a patented, extended-release oral formulation: a unique fixed-dose combination of two FDA-approved drugs that targets multiple ALS-relevant pathways. In PARADIGM PrimeC was well tolerated and over 18 months, reduced functional decline by 32.8% (p=0.007), improved bulbar function, favorably modulated key biomarkers and significantly improved ALS complication-free survival at 18 months (p=0.02). If you’re at NEALS, join us for the talk, and our poster, “From PARADIGM to PARAGON.”
#NEALS2025
#ALS
#PrimeC
$NRSN
Another step forward for PrimeC.
Today we shared new biomarker findings from our PARADIGM study, showing that PrimeC significantly reduced several key microRNAs linked to Alzheimer’s disease biology - pathways related to neuroinflammation, amyloid and tau.
While this reinforces PrimeC’s multi-target mechanism, our main focus remains clear: advancing our Phase 3 program in ALS and bringing this therapy to the people who need it most.
There’s nothing standing in our way - science, determination, and purpose continue to guide us.
$NRSN
#PrimeC
#ALS
#Alzheimers
#Neurodegeneration
You are more than welcome to submit your questions before or during the live event. 🙂
$NRSN
What happens when Broadway star Aaron Lazar - now a fearless ALS advocate, sits down again with NeuroSense CEO Alon Ben-Noon, continuing a moving conversation they began not long ago?
A powerful live conversation on breakthrough ALS science, PrimeC’s path to market, and hope for a community that needs it most.
🎙️ Live on Aug 4th at 2pm EST.
💡 Expect insider insights $NRSN, real talk, and audience Q&A.
👉 Join us for this must‑watch event:
finance.yahoo.com/news/award…
$NRSN
A lot is going on at NeuroSense Therapeutics.
Here are some updates of what we did in the second quarter of this year.
Watch here 👇
youtu.be/bo4ZNja0Pqc?si=Keb-…
Full steam ahead! We're ramping up manufacturing with our partners at Recipharm to ensure we're ready for market. Looking forward to big updates very soon. Stay tuned!
$NRSN
$NRSN
Got a few questions today about whether we're planning a private placement. 🤨
The plain answer: No. Now's not the time.
We believe there are better options ahead for the company - and we're focused on those.
$NRSN Good news, and more to come.
finance.yahoo.com/news/neuro…
I’m the Luckiest Man on Earth.
This ALS Awareness Month, we honor the strength of patients & families - and keep pushing forward.
At @NeuroSenseTX, every step we take is for them - and yes, we’re on the right path, on all fronts.
#ALSAwarenessMonth
#ALS
#Hope
#PrimeC
$NRSN
linkedin.com/posts/alonbn_th…
$NRSN Today I shared a letter to shareholders providing an overview and updates on how we're advancing on multiple fronts, including Phase 3 preparations for PrimeC in ALS, Canadian regulatory pathway progress, our recent clinical validation, and our ongoing partnership discussions with a leading global pharmaceutical company.
We remain optimistic about these ongoing talks that we believe have the potential to bring forth a truly transformative result for our company and ALS patients.
I also want to take this opportunity to thank our shareholders and stakeholders for their continued support and confidence. Our entire team is working very hard and we are committed to creating value for our investors bringing hope to those suffering from this debilitating disease.
prnewswire.com/news-releases…